Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 2
1995 3
1996 1
1997 2
1998 21
1999 57
2000 85
2001 192
2002 345
2003 414
2004 592
2005 714
2006 768
2007 912
2008 898
2009 915
2010 931
2011 923
2012 1015
2013 1032
2014 1090
2015 1017
2016 1123
2017 1075
2018 1063
2019 1048
2020 790
Text availability
Article attribute
Article type
Publication date

Search Results

15,080 results
Results by year
Filters applied: . Clear all
Page 1
Psoriasis.
Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, Mehta NN, Finlay AY, Gottlieb AB. Greb JE, et al. Nat Rev Dis Primers. 2016 Nov 24;2:16082. doi: 10.1038/nrdp.2016.82. Nat Rev Dis Primers. 2016. PMID: 27883001 Review.
Infliximab-Related Infusion Reactions: Systematic Review.
Lichtenstein L, Ron Y, Kivity S, Ben-Horin S, Israeli E, Fraser GM, Dotan I, Chowers Y, Confino-Cohen R, Weiss B. Lichtenstein L, et al. J Crohns Colitis. 2015 Sep;9(9):806-15. doi: 10.1093/ecco-jcc/jjv096. Epub 2015 Jun 19. J Crohns Colitis. 2015. PMID: 26092578 Free PMC article. Review.
Three RCTs evaluated infusion reactions as a secondary outcome; another four RCTs included infusion reactions in the safety evaluation analysis; and 62 additional studies focused on various aspects of mechanism/s, risk, primary and secondary preventive measures, and manage …
Three RCTs evaluated infusion reactions as a secondary outcome; another four RCTs included infusion reactions in the safety evaluation analy …
The pharmacotherapeutic management of pediatric Crohn's disease.
Zimmerman L, Bousvaros A. Zimmerman L, et al. Expert Opin Pharmacother. 2019 Dec;20(17):2161-2168. doi: 10.1080/14656566.2019.1659778. Epub 2019 Oct 1. Expert Opin Pharmacother. 2019. PMID: 31574236 Review.
Introduction: Crohn's disease (CD) is a chronic inflammatory condition that can occur throughout the gastrointestinal tract. ...Immunomodulators (thiopurines, methotrexate) and biologics (infliximab, adalimumab) may be employed for maintenance of remission to preven …
Introduction: Crohn's disease (CD) is a chronic inflammatory condition that can occur throughout the gastrointestinal tract. ...Immun …
Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.
Wong U, Cross RK. Wong U, et al. Expert Opin Drug Metab Toxicol. 2017 Oct;13(10):1039-1046. doi: 10.1080/17425255.2017.1377180. Epub 2017 Sep 11. Expert Opin Drug Metab Toxicol. 2017. PMID: 28876147 Review.
Primary and secondary non-response to infliximab are common in patients with inflammatory bowel disease and remain a management challenge in clinical practice. ...An algorithm for evaluation and management of non-response to infliximab is provided. Preventative meas …
Primary and secondary non-response to infliximab are common in patients with inflammatory bowel disease and remain a management chall …
SB2: An Infliximab Biosimilar.
Lamb YN, Scott LJ, Deeks ED. Lamb YN, et al. BioDrugs. 2017 Oct;31(5):461-464. doi: 10.1007/s40259-017-0240-7. BioDrugs. 2017. PMID: 28803431 Review.
SB2 is a biosimilar of the reference anti-TNF-α antibody infliximab. In May 2015, it was approved in the EU for use in all indications for which reference infliximab is approved, including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerat …
SB2 is a biosimilar of the reference anti-TNF-α antibody infliximab. In May 2015, it was approved in the EU for use in all indication …
PF-06438179/GP1111: An Infliximab Biosimilar.
Al-Salama ZT. Al-Salama ZT. BioDrugs. 2018 Dec;32(6):639-642. doi: 10.1007/s40259-018-0310-5. BioDrugs. 2018. PMID: 30284704 Free PMC article. Review.
PF-06438179/GP1111 (Zessly(®); Ixifi(®)) [hereafter referred to as GP1111] is a biosimilar of the reference monoclonal anti-TNF-α antibody infliximab, and is approved in the EU and USA for the same indications as the reference drug, including rheumatoid arthritis (RA), Cro …
PF-06438179/GP1111 (Zessly(®); Ixifi(®)) [hereafter referred to as GP1111] is a biosimilar of the reference monoclonal anti-TNF-α antibody …
Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease.
Hemperly A, Vande Casteele N. Hemperly A, et al. Clin Pharmacokinet. 2018 Aug;57(8):929-942. doi: 10.1007/s40262-017-0627-0. Clin Pharmacokinet. 2018. PMID: 29330783 Review.
Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and adult patients with moderately to severely active Crohn's disease (CD) and ulcerative colitis (UC). ...The administration of infliximab is weight-based and the drug
Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and adult patients with moderately to seve
Infliximab for the treatment of CNS sarcoidosis: A multi-institutional series.
Gelfand JM, Bradshaw MJ, Stern BJ, Clifford DB, Wang Y, Cho TA, Koth LL, Hauser SL, Dierkhising J, Vu N, Sriram S, Moses H, Bagnato F, Kaufmann JA, Ammah DJ, Yohannes TH, Hamblin MJ, Venna N, Green AJ, Pawate S. Gelfand JM, et al. Neurology. 2017 Nov 14;89(20):2092-2100. doi: 10.1212/WNL.0000000000004644. Epub 2017 Oct 13. Neurology. 2017. PMID: 29030454 Free PMC article.
OBJECTIVE: To describe clinical and imaging responses in neurosarcoidosis to infliximab, a monoclonal antibody against tumor necrosis factor-α. ...RESULTS: Of 66 patients with CNS sarcoidosis (27 definite, 39 probable) treated with infliximab for a median of 1.5 yea …
OBJECTIVE: To describe clinical and imaging responses in neurosarcoidosis to infliximab, a monoclonal antibody against tumor necrosis …
Biosimilars in rheumatology.
Araújo FC, Gonçalves J, Fonseca JE. Araújo FC, et al. Pharmacol Res. 2019 Nov;149:104467. doi: 10.1016/j.phrs.2019.104467. Epub 2019 Sep 27. Pharmacol Res. 2019. PMID: 31568820 Review.
The landmark approval of CT-P13 as the first infliximab biosimilar paved the way for new infliximab but also etanercept, adalimumab and rituximab biosimilars. ...
The landmark approval of CT-P13 as the first infliximab biosimilar paved the way for new infliximab but also etanercept, adali …
Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience.
Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW Jr, Langholff W, Sandborn WJ. Lichtenstein GR, et al. Inflamm Bowel Dis. 2018 Feb 15;24(3):490-501. doi: 10.1093/ibd/izx072. Inflamm Bowel Dis. 2018. PMID: 29462395 Free PMC article. Clinical Trial.
BACKGROUND: The purpose of this study was to compare the long-term safety of infliximab and nonbiologic agents as Crohn's disease (CD) therapy. ...Infliximab dose was not associated with mortality or serious infection. An increased risk of serious infection w …
BACKGROUND: The purpose of this study was to compare the long-term safety of infliximab and nonbiologic agents as Crohn's dise …
15,080 results
Jump to page
Feedback